Biotech News
Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona
Safety profile to date with continuous daily dosing supports continued dose optimization and clinical development Pharmacodynamic data demonstrate WEE1 target engagement across multiple doses, pharmacokinetics support once-daily administration Planned expansion into focused cohorts in uterine
